

FOR IMMEDIATE RELEASE

**Perthera to Exhibit at the American Society of Clinical Oncology (ASCO)
2018 Annual Meeting**

McLean, VA, May 14, 2018— [Perthera, Inc.](#), the leading Therapeutics Intelligence Company™, is attending the 2018 ASCO Annual Meeting at McCormick Place, Chicago, IL, June 1-5, 2018. Perthera science and clinical results will be represented in a Podium Presentation, 2 Poster Presentations and a Symposium Breakfast. Perthera will also be exhibiting at booth #16024 from Saturday June 2nd – Monday June 4th.

"We are very excited to attend ASCO this year, and very proud to have our scientific and clinical results presented. We will be presenting the value of our Perthera Report™ and Perthera Precision Medicine™ to oncologists attending the conference. Our presentations demonstrate how effective our Perthera Report is in aiding oncologists in their treatment decisions for their patients, as well as improving outcomes for those patients." Neal G. Koller, President & CEO, Perthera, Inc.

Perthera's presentations at the 2018 ASCO Annual Meeting:

- A Cloud-Based Virtual Tumor Board to Facilitate Treatment Recommendations for Patients with Advanced Cancers (Abstract 6508)
Podium presentation
Subha Madhavan Ph.D.
Health Services Research, Clinical Informatics, and Quality of Care Session
June 1st from 2:45 – 5:45 pm
- Precision Medicine for Pancreatic Cancer Patients - Preliminary Results from the Know Your Tumor Program (Abstract 4126)
Poster presentation
Gastrointestinal (Noncolorectal) Cancer Session
June 3rd from 8:00 – 11:00 am
- Outcome driven persona-typing for precision oncology: Beyond Genomics Centered View of Individualized Therapy (Abstract 4130)
Poster presentation
Gastrointestinal (Noncolorectal) Cancer Session
June 3rd from 8:00 – 11:00 am

ABOUT PERTHERA, INC.

Perthera is the leading Therapeutic Intelligence Company advancing precision medicine through its Perthera Report, which precisely matches cancer patients with multiple therapeutic options ranked by highest probability of best outcome. www.perthera.com

Contact Information

Phil Robertson
+1 (703) 286-0780
phil.robertson@perthera.com

###

Safe Harbor Statement:

The statements in the press release that relate to Perthera, Inc. (the "Company") expectations with regard to the future impact on the Company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties which could cause the Company's actual operating results, performance, business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.